600513.SH
联环药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.64
−6.01%Aug 28, 2026, 09:49 UTC
Lianhuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 10.5218 million yuan, turning from a loss in the same period last year.
Aug 11, 2026, 09:27 UTC
Lianhuan Pharmaceutical's board approved its subsidiary Lianhuan (Nanjing) Medical Technology to borrow 10 million yuan from related party Jiangsu Lianhuan Health Industry Management Development at an annual interest rate of 2.5% for up to 3 months.
Source:Aug 11, 2026, 09:27 UTC
Lianhuan Pharmaceutical's board approved its subsidiary Sichuan Longyi Pharmaceutical to apply for a comprehensive credit line of up to 271 million yuan from banks, effective until the 2026 annual shareholders' meeting.
Source:Jul 21, 2026, 08:38 UTC
Lianhuan Pharmaceutical and its subsidiary Lianhuan Marketing signed project entry contracts with Yangzhou High-tech Zone Management Committee for two investment projects totaling 450 million yuan.
Source: